# **cAMP** prevents antibody-mediated thrombus formation in COVID-19

1

29

2 3 Jan Zlamal<sup>1\*</sup>, Karina Althaus<sup>1,2\*</sup>, Hisham Jaffal<sup>1</sup>, Lisann Pelzl<sup>1</sup>, Anurag Singh<sup>1</sup>, Andreas Witzemann<sup>1</sup>, Helene Häberle<sup>3</sup>, Valbona Mirakaj<sup>3</sup>, Peter Rosenberger<sup>3</sup> and Tamam 4 Bakchoul<sup>1,2</sup> 5 6 7 <sup>1</sup>Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, 8 University Hospital of Tuebingen 9 <sup>2</sup>Centre for Clinical Transfusion Medicine, University Hospital of Tuebingen 10 <sup>3</sup>Department of Anesthesiology and Intensive Care Medicine, University Hospital of 11 Tuebingen 12 \* Indicates equal contribution 13 14 Running title: cAMP prevents antibody-induced procoagulant platelets 15 Tables: 1 16 Figures: 10 17 18 Key words: procoagulant platelet, Fc-gamma-receptor IIA, COVID-19, cAMP 19 20 Corresponding author: 21 Tamam Bakchoul, MD 22 University Hospital of Tuebingen 23 Otfried-Müller-Straße 4/1 24 72076 Tübingen 25 Tel: +49-(0)7071 / 29-81601, Fax: +49-(0)7071 / 29-5240 E-mail: tamam.bakchoul@med.uni-tuebingen.de 26 27 28

# **Key points**

30

35

- Fc-gamma-receptor IIA mediated PS externalization on the PLT surface 31 triggers increased thrombus formation 32
- 33 Inductors of cAMP inhibit antibody-mediated thrombus formation and may have potential therapeutic advantage in COVID-19 34

Abstract

Thromboembolic events are frequently reported in patients infected with the SARS-CoV-2 virus. However, the exact mechanisms of thromboembolic events remain elusive. In this work, we show that immunoglobulin G (IgG) subclass in patients with COVID-19 trigger the formation of procoagulant PLTs in a Fc-gamma-RIIA (FcγRIIA) dependent pathway leading to increased thrombus formation in vitro. Most importantly, these events were significantly inhibited via FcγRIIA blockade as well as by the elevation of PLTs' intracellular cyclic-adenosine-monophosphate (cAMP) levels by the clinical used agent Iloprost. The novel findings of FcγRIIA mediated prothrombotic conditions in terms of procoagulant PLTs leading to higher thrombus formation as well as the successful inhibition of these events via Iloprost could be promising for the future treatment of the complex coagulopathy observed in COVID-19 disease.

## Introduction

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

Infection with SARS-CoV-2 has been shown to be associated with abnormalities in the coagulation system with an increased incidence of thromboembolic events in small vessels leading to higher mortality (1-3). Accumulating evidence suggests upregulated release of inflammatory cytokines and increased interaction between different actors of innate and adaptive immunity as the main causes for the prothrombotic environment observed in COVID-19 disease (4). Moreover, a significant number of reports described platelet (PLT) hyperactivity in patients with COVID-19, which is assumed to contribute to prothrombotic conditions (5, 6). Procoagulant PLTs, predominantly generated at the outer side of the growing thrombus, are increasingly recognized to link primary with secondary haemostasis (7-10). The latter is mainly executed by negatively charged membrane phospholipids externalized on the PLT surface. This unique feature of procoagulant PLTs enables the assembly of tenase as well as prothrombinase complexes leading to high thrombin burst, increased fibrin deposition and thrombus formation (11). Recently, we showed that PLTs from patients with severe COVID-19 infection express a procoagulant phenotype. Immunoglobulin G (IgG) fractions were found to be responsible for the COVID-19 induced procoagulant PLTs (Althaus et al. accepted). In the current study, we investigate the time course of the generation of antibody- induced procoagulant PLTs as well as the mechanisms leading to alterations in the PLT phenotype in COVID-19. We observed that IgG fractions from severe COVID-19 patients induce increased thrombus formation in an Fc-gamma RIIA (FcyRIIA) dependent manner. More importantly, we were able to show that cyclic-adenosine-monophosphate (cAMP) elevation in PLTs prevents COVID-19 antibody-induced procoagulant PLT generation as well as clot formation.

# **Materials and Methods**

Patients and sera

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

Experiments were performed using leftover serum material from COVID-19 patients who were referred to our laboratory between March and June 2020. The diagnosis of SARS-CoV-2 infection was confirmed by real time PCR on material collected by nasal swabs. Sera from ICU non-Covid-19 patients with postoperative sepsis were collected to serve as ICU control group. Additionally, sera were collected from healthy blood donors at the Blood Donation Centre Tuebingen after written consensus was obtained to establish cutoff values when appropriate. Serum samples were stored at -80°C and thawed at room temperature prior to the performed experimental procedure. All sera were heat-inactivated at 56°C for 30 minutes (min), which was followed by a centrifugation step at 5000xg. The spun-down was discarded and supernatants were handled as described in the following sections. IgG preparation IgG fractions were isolated by the use of a commercially available IgG-purification-kit (Melon<sup>TM</sup>-Gel IgG Spin Purification Kit, Thermo Fisher Scientific, Waltham, USA) and used as recommended by the manufacturer. In brief, heat inactivated serum was diluted 1:10 in purification buffer and incubated with the kit specific Gel IgG Purification Support over four cycles for 10 min. Subsequently, periodically performed centrifugation steps through a 10 µm pore size filter tube were performed for 1 min at 5000xg. The flow throw was collected into 100 kDa-pore sized centrifugal filters (Amicon Ultra-4, Merck Millipore, Cork, Ireland) with subsequent concentration to the initial volume of the used serum sample via centrifugation (10-15 min, 2000xg, 4°C,

with brake). Afterwards, IgG concentrations were measured at a mass extinction

coefficient of 13.7 at 280 nm wavelength using a NanoDrop One spectrophotometer (VWR, Bruchsal, Germany). IgG purity was verified using Coomassie staining (Abcam, Cambridge, UK).

### Preparation of washed platelets

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

Washed platelets (wPLTs) were prepared from venous blood samples as described previously (12). Briefly, whole blood from healthy donors was withdrawn by cubital venipuncture into acidic-dextrose containing vacutainers (Becton-Dickinson, Plymouth, UK) and allowed to rest for 45 min at 37°C. After centrifugation (20 min, 120xg, room temperature [RT], no brake) PLT-rich-plasma (PRP) was gently separated and supplemented with apyrase (5 µL/mL, Sigma-Aldrich, St. Louis, USA) and prewarmed ACD-A (111 µL/mL, Terumo BCT, Inc., Lakewood, USA). After an additional centrifugation step (7 min, 650xg, RT, no brake), the PLT pellet was resuspended in 5 mL of wash-solution (modified Tyrode buffer: 5 mL bicarbonate buffer, 20 percent (%) bovine serum albumin, 10% glucose solution [Braun, Melsungen, Germanyl, 2.5 U/mL apyrase, 1 U/mL hirudin [Pentapharm, Basel, Swiss], pH 6.3) and allowed to rest for 15 min at 37°C. Following final centrifugation (7 min, 650xg, RT, no brake) wPLTs were resuspended in 2 mL of resuspensionbuffer (50 mL of modified Tyrode buffer, 0.5 mL of 0.1 M MgCl2, 1 mL of 0.2 M CaCl2, pH 7.2) and adjusted to 300x109 PLTs/L after the measurement at a Cell-Dyn Ruby hematological analyzer (Abott, Wiesbaden, Germany) was performed. For calcium chelation experiments, the PLT pellet was resuspended with resuspensionbuffer without the supplementation of calcium (50 mL of modified Tyrode buffer, 0.5 mL of 0.1 M MgCl2, pH 7.2).

### Treatment of wPLTs with ICU COVID-19 sera/lgG

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

wPLTs (7.5x10<sup>6</sup>) were supplemented with 5 µL serum/lgG from ICU COVID-19 patients or control serum/IgG and incubated for 1.5 hours (hs) at RT under rotating conditions. Afterwards, samples were washed once (7 min, 650xg, RT, no brake), resuspended in 100 µL of phosphate buffered saline (PBS, [Biochrom, Berlin, Germany]) and further handled as described in the following sections. Detection of phosphatidy/serine exposure To assess externalization of phosphatidylserine (PS) on the PLT surface after antibody treatment, 10 µL of PLT suspension were transferred into 100 µL of Hank's balanced salt solution (HBSS), (137 mM NaCl, 1.25 mM CaCl<sub>2</sub>, 5.5 mM glucose, [Carl-Roth, Karlsruhe, Germany]) and incubated with 1 µL Annexin V-FITC (Immunotools, Friesoythe, Germany) for 30 min at RT in the dark. To induce the maximal externalization of PS on the PLT surface, wPLTs were incubated with ionomycin (Sigma-Aldrich, St. Louis, USA, [5 µM, 15 min at RT]). Afterwards, PLTs were filled up with HBSS to a final volume of 500 µL and acquired at a flow cytometer ([FC], Navios, Beckman-Coulter, Brea, USA). PLTs were gated based on their characteristic forward scatter (FSC) vs. side scatter (SSC) properties as well as CD41a and CD42a expression (anti-CD41a-PC5 and anti-CD42a-PerCP, both BD, San Jose, USA), respectively. Test results were analyzed as fold increase of the percentage PS positive PLTs compared to PLTs that were incubated with serum/IgG from healthy individuals. Determination of changes in the inner-mitochondrial-transmembrane potential  $(\Delta \Psi)$ Changes of the mitochondrial inner transmembrane potential ( $\Delta\Psi$ ) induced by ICU

COVID-19 sera/IgG were analyzed by FC, as previously reported (13). Briefly, after

treatment with IgG/serum from ICU COVID-19 patients, wPLTs (~2x10<sup>6</sup>) were incubated with a final concentration of 10  $\mu$ M tetramethylrhodamine, ethyl ester (TMRE, Abcam, Cambridge, UK) for 30 min at RT in the dark. Carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP, Abcam, Cambridge, UK) which is an uncoupler of mitochondrial oxidative phosphorylation served as positive control in each experiment. After staining with TMRE, PLTs were filled up with PBS to a final volume of 500  $\mu$ L and immediately analyzed by FC. Changes in the  $\Delta\Psi$  were determined in gated PLTs as percentage of TMRE negative events and normalized to PLTs that were treated with serum/IgG from healthy controls.

#### Phenotyping of different PLT-populations

ICU COVID-19 serum/IgG-mediated procoagulant changes (PS/CD62p-double positive) were assessed in some experiments using a triple staining. Briefly, 10 μL (~1x10<sup>6</sup>) of the resuspended PLT suspension were transferred into 10 μL of HBSS and incubated with 1 μL anti-CD62p-APC (BD, San Jose, USA), 1 μL Annexin-FITC (Immunotools, Friesoythe, Germany) and 1 μL anti-CD42a-PerCP (BD, San Jose, USA) for 15 min at RT in the dark. PLTs treated with thrombin receptor activating peptide (TRAP-6, [20 μΜ, 30 min at RT]) and ionomycin (5 μΜ, 15 min at RT, [both Sigma-Aldrich, St. Louis, USA]) served as positive controls. Afterwards, PLTs were resuspended with HBSS to a final volume of 500 μL and immediately assessed via FC. In selected experiments that were designed to investigate the impact of calcium on cell signalling, PLT PS externalization was assessed by the use of the calcium independent marker lactadherin. 1 μL of lactadherin-FITC (Haematologic Technologies, Essex Junction, USA) was incubated with wPLTs as for Annexin-FITC for 15 min at RT, in the dark, and the PLT suspension filled up to final volume of 500 μL with PBS prior to FC analysis.

#### Western blot analysis of caspase 3 cleavage

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

Protein levels of cleaved-caspase 3 were determined by western blot. After serum/IgG incubation, cells were washed with PBS for 7 min, 700xg at 4°C. Subsequently, the pellet was resuspended in 100 µL of ice-cold RIPA lysis buffer containing HALT<sup>TM</sup> protease and phosphatase inhibitor-cocktail (both ThermoFisher Scientific, Paisley, UK). Protein concentrations were determined using the NanoDrop One spectrophotometer (VWR, Bruchsal, Germany). 100 µg of protein was solubilized in sample buffer (Invitrogen<sup>TM</sup>, Carlsbad, USA) at 95°C for 10 min. Proteins were separated by electrophoresis using 12% SDS-PAGE gels in glycinetris buffer. Thereafter, probes were transferred to polyvinylidene difluoride (PVDF) membranes (0.45 µm, Merck, Tullagreen, Ireland). Afterwards, membranes were blocked with 5% milk in tris-buffered saline (TBS-T, 20 mM Tris, 140 mM NaCl, 0.1% Tween, pH 7.6) at RT for 1 h. Membranes were then incubated with primary antihuman cleaved-caspase 3 antibody (1:1000, Abcam, Cambridge, UK) and antihuman alpha-tubulin (1:1000, Cell Signaling Technology, Danvers, USA) at 4°C overnight. After washing with TBS-T buffer, the membranes were incubated with the appropriate secondary anti-rabbit or anti-mouse antibody conjugated with IRDye<sup>®</sup>680 / IRDye®800 (1:3000, LI-COR®, Lincoln, USA) for 1 h at RT. Protein bands were detected after additional washes (TBS-T) with Odyssey infrared imaging system (LI-COR®, Lincoln, USA). Western blots were analyzed by ImageJ software (NIH, Bethesda, USA). The results are shown as the ratio of total cleaved-caspase 3 to procaspase 3 (full fragment) and normalized to wPLTs that were treated with healthy control serum/lgG.

#### Assessment of the mechanisms of antibody-mediated effects on PLTs

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

75 µL wPLTs were pretreated with the FcvRIIA blocking monoclonal antibody (moAb) anti-CD32 (5 µL moAb IV.3; stemcell™ technologies, Vancouver, Canada) for 45 min at 37°C prior to serum/IgG treatment. A monoclonal isotype (moAb) served as vehicle control ([SC-2025], Santa Cruz Biotechnology, Dallas, USA). For the chelation of extracellular calcium, the non-membrane permeable chelator of extracellular calcium EGTA (Ethyleneglycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid, 1 mM, 5 min at 37°C [Sigma Aldrich, St. Louis, USA]) was used. For the depletion of calcium in the inner compartment of PLTs, the intracellular chelator of calcium BAPTA-AM (1,2-Bis(2-aminophenoxy)ethane-N,N,N',N'tetraacetic acid tetrakis(acetoxymethyl) ester, 20 µM, 15 min at 37°C, [Selleck, Houston, USA]) was used. To investigate the effect of increased intracellular levels of cAMP, wPLTs were pretreated with the adenvlate cyclase (ADC) inducers Forskolin (2.25 µM) and lloprost (20 nM, both Sigma-Aldrich, St. Louis, USA) prior to the incubation with sera/IgGs from ICU COVID-19 patients. Investigations of antibody-mediated thrombus formation To assess the impact of ICU COVID-19 IgG-induced effects on clot formation, an ex vivo model for thrombus formation was established. A microfluidic system (BioFlux, Fluxion Biosciences, Alameda, USA) was used at a shear rate of 1500<sup>-1</sup> (60 dyne) according to the recommendations of the ISTH standardization committee for biorheology (14). Briefly, microfluidic channels were coated with collagen (100 μg/mL, Collagen Horm, Takeda, Linz, Austria) overnight at 4°C and blocked with

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

2.5% of human serum albumin (HSA, Kedrion, Barga, Italy) 1 h before perfusion at RT. Whole blood samples of healthy individuals of blood group O were collected into hirudin containing monovettes (Sarstedt, Nuembrecht, Germany) and allowed to rest for 30 min at RT. After splitting the whole blood into aliquots of 200 µL, PRP was prepared via centrifugation (20 min, 120xg, at RT, no break). Afterwards, 45 µL of the supernatant PRP was gently separated and incubated with 5 µL of control or ICU COVID-19 IgG fractions and incubated for 90 min at RT under rotating conditions. 15 min prior to the end of the incubation period, Calcein-FITC (4 µM, [Thermo Scientific, Eugene, Oregon, USA]) was added to each sample. Subsequently, PRP was gently added back to reconstitute whole blood samples. When indicated, the separated PRP was pretreated with moAb IV.3 or moAb isotype control at a concentration of 20 µg/mL for 30 min at RT. For cAMP induction, PRP was pretreated with lloprost (20 nM) or vehicle control (5 min, 37°C) prior to IgG incubation. Finally, reconstituted whole blood samples were run at a shear rate of 1500s<sup>-1</sup> (60 dyne) for a maximum of 5 min. Immunofluorescence and bright field images were taken from 3-5 randomly chosen microscopic fields (x20, Olympus IX73, Olympus GmbH, Hamburg, Germany). Clot formation was assessed by measuring the % of surface area coated by thrombus (SAC) of 3-5 images via ImageJ (NIH, Bethesda, USA) and normalized to the whole area. Statistical analysis Statistical analyses were performed using GraphPad Prism 7 (La Jolla, USA). T-test was used to analyze normally distributed results. Non-parametric test (Mann-Whitney test) was used when data failed to follow a normal distribution as assessed by

D'Agostino and Pearson omnibus normality test. Group comparison was performed using the Wilcoxon rank-sum test and the Fisher exact test with categorical variables.

A p-value <0.05 was assumed to represent statistical significance.

Ethics

Studies involving human material were approved by the Ethics Committee of the Medical Faculty, Eberhard-Karls University of Tuebingen, Germany, and were

conducted in accordance with the declaration of Helsinki.

Results

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

Patient characteristics

Sera from 26 ICU COVID-19 patients were enrolled in this study between March the 1st and June the 16th 2020. 21 of these ICU COVID-19 patients were included in a previous study (Althaus et al. accepted). The mean age of ICU COVID-19 patients was 58 years (range: 29-88 years). 20/30 (67%) patients had known risk factors for severe COVID-19 infection as described previously (15), including hypertension 18/30 (60%), obesity 6/30 (20%), coronary artery disease 4/30 (13%) and diabetes mellitus 6/30 (20%). Elevated D-Dimer levels were detected in all patients (median, range: 3.4 mg/dL, 0.9-45.0 mg/dL) and thrombosis was diagnosed in 13/30 (43%) patients. Longitudinal blood samples were available from four COVID-19 patients who were first admitted to normal ward and later to the ICU for mechanical ventilation. As ICU control group, 5 patients who were admitted to ICU due to non-COVID-19 related causes were included in this study. Sera from ICU COVID-19 patients induce progressive increase of procoagulant **PLTs** To investigate whether sera of ICU COVID-19 patients have the potential to induce an increased  $\Delta \psi$  depolarization as well as PS externalization on the PLT surface, wPLTs from healthy individuals were incubated with sera from 26 ICU COVID-19 patients with a severe course of disease as well as 5 ICU non-COVID-19 patients. Based on the calculated cuttoffs (mean+2xSD of healthy controls), 19/26 (73%) sera from patients with severe COVID-19 disease induced significantly higher Δψ depolarization in PLTs from healthy donors compared to ICU controls (FI in %  $\Delta \psi$ depolarization±SEM: 6.10±1.12 vs. 0.67±0.10, p value <0.0001, Fig. 1 A). In addition, perpetuity.
All rights reserved. No reuse allowed without permission.

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

significantly higher PS externalization was observed when ICU COVID-19 sera were incubated with PLTs compared to ICU control sera (FI in % PS±SEM: 2.12±0.19 vs. 1.12±0.08, p value <0.0001, Fig. 1 B). Next, we sought to investigate the time course of the observed changes in both markers. Longitudinal blood samples were available from four ICU COVID-19 patients. Sera were collected at hospital admission (normal ward or ICU) and during a follow up period at ICU for up to 14 days. As shown in Fig. 1 C-F, sera from ICU COVID-19 patients induced significant changes in Δψ depolarization, PS externalization and caspase 3 cleavage as clinical manifestation worsen requiring admission to ICU. Of note, antibody-induced changes peaked within day 3 and 7 of the ICU stay (FI in % Δψ depolarization±SEM: 3.71±0.72, p value 0.0070; and % PS externalization ±SEM: 4.80±1.11, p value <0.0001, respectively, Suppl. Fig. 1). These findings were further supported by WB analyses, as PLTs incubated with the corresponding ICU COVID-19 serum induced caspase 3 cleavage in similar kinetic (Ratio of cleaved caspase 3/procaspase 3 normalized to control±SEM: 4.84±0.45, p value 0.0035, Fig. 1 E+F). Notably, the rise of PLT markers was associated with increasing levels of detected IgGs against the spike S protein of SARS-CoV-2 in the corresponding ICU COVID-19 patients' follow up sera but not in the total IgG contents of isolated IgG fractions (Suppl. Fig. 2 A and B, respectively). Moreover, declining PLT-counts were observed as Δψ depolarization as well as PS externalization increased, vice versa (Suppl. Fig. 3 A and B, respectively). IgGs from severe COVID-19 trigger procoagulant PLTs with increased ability to form blood clots To further verify the impact of sera from severe COVID-19 patients on PLTs, the expression of the alpha granule release and PLT activation marker CD62p was

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

analyzed in two colour FC in parallel to PS. FC analyses revealed that IgG fractions from severe COVID-19 patients induce remarkable changes in the PLT SSC and FSC (Fig. 2.1. A+C), as well as in the distribution of CD62p/PS positivity (Fig. 2.1. B+D). In contrast, the PLT population was almost non-affected after incubation with IgGs from healthy controls (HCs) or ICU non-COVID-19 control patients. Overall, higher percentage of double positive events was observed after incubation with IgGs from ICU COVID-19 patients compared to ICU and to HCs (% CD62p/PS positive PLTs±SEM: 31.63±3.86 vs. 4.04±1.16, p value 0.0007; and vs. 2.88±0.52, p value <0.0001, respectively, Fig. 2.1. II.). Additionally, significant elevation was observed in the PS single positive PLT population (% PS positive PLTs±SEM: 13.17±2.05 vs. 2.66±0.52, p value <0.0001; and vs. 2.36±0.29, p value 0.0002, Fig. 2.1. I) but not in the percentage of CD62p single positive PLTs (% CD62p positive PLTs±SEM: 19.40±1.83 vs. 13.53±1.90, p value 0.1011, Fig. 2.1. III). Next, we sought to investigate the ability of IgG fractions from patients with severe COVID-19 to cause increased clot formation. PLTs from healthy individuals were incubated with IgGs from ICU COVID-19 patients or ICU and HCs, added to autologous whole blood samples and finally perfused throw collagen covered microfluidic channels at a shear rate of 1500 s<sup>-1</sup> (60 dyne). As shown in Fig. 3 A, IgG from severe COVID-19 patients caused increased clot formation. Overall, significantly higher surface area coverage by thrombus (SAC) was observed in the presence of ICU COVID-19 IgGs compared to ICU controls and HCs (mean % SAC±SEM: 13.95%±1.55 vs. 2.86±1.10, p value 0.0070; and vs. 2.70±0.83, p value 0.0002, respectively, Fig. 3 B). Together with the increased percentage of procoagulant PLTs (CD62p/PS positive) in response to ICU COVID-19 IgGs, these findings might provide a potential explanation for the increased thromboembolic events in severely affected COVID-19 patients.

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

procoagulant PLTs

ICU COVID-19 IgGs cause procoagulant PLTs via crosslinking FcyRIIA To further determine the underlying mechanistic pathways leading to ICU COVID-19 IgG induced formation of procoagulant PLTs, we next considered a potential ligation of FcyRIIA by patients, sera/IgGs. For this purpose, wPLTs were pretreated with the moAb IV.3. This FcyRIIA blockade resulted in marked inhibition of the antibodyinduced Δψ depolarization (FI in % Δψ depolarization±SEM: 5.51±0.94 vs. 1.18±0.08, p value 0.0020, Fig. 4.1. A) as well as significant reduction of caspase activation (Ratio of cleaved caspase 3/procaspase 3±SEM: 4.70±1.16 vs. 1.33±0.29, p value 0.0286, Fig. 4.1. B+C). Intriguingly, the blockade of FcyRIIA almost abolished the changes in PLTs' FSC and SSC properties (Fig. 4.2. A+C), and markedly reduced CD62p/PS double positive PLT population compared to isotype-control (% CD62p/PS positive PLTs±SEM: 48.91±3.05 vs. 12.88±1.65, p value 0.0078, Fig. 4.2. II). Next, we analyzed the impact of FcyRIIA blockade on antibody-mediated clot formation. Pretreatment of PLTs with moAb IV.3 prior to ICU COVID-19 IgG incubation resulted in significant reduction of clot formation compared to isotypecontrol (mean % SAC±SEM: 16.49±1.02 vs. 5.84±1.93, respectively, p value 0.0090, Fig. 5 A+B). These results indicate that ICU COVID-19 IgG antibodies that are present in a subgroup of severe ICU COVID-19 patients have the capability to induce formation of procoagulant PLTs with increased clotting ability via crosslinking FcyRIIA. Calcium is pivotal for the generation of ICU COVID-19-lgG induced

perpetuity.
All rights reserved. No reuse allowed without permission.

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

Following the detection of an ICU COVID-19 IgG-induced procoagulant PLT phenotype, we sought to investigate the underlying intracellular molecular mechanisms. The contribution of calcium was analyzed by the depletion of extra- and intracellular calcium contents via EGTA and BAPTA, respectively. Extracellular calcium depletion caused significant inhibition of  $\Delta \psi$  depolarization (FI in %  $\Delta \psi$ depolarization±SEM: 3.08±0.18 vs. 1.94±0.20, p value 0.0079, Fig. 6.1. A) as well as marked reduction of caspase 3 cleavage (Ratio of cleaved caspase 3/procaspase 3±SEM: 4.14±0.65 vs. 1.50±0.20, p value 0.0079, Fig. 6.1. B+C). Moreover, depletion of extracellular calcium significantly inhibited ICU COVID-19 IgG induced alterations of wPLTs' morphology (Fig. 6.2. A-D) as well as the generation of CD62p/PS positive PLTs (% CD62p/PS positive PLTs±SEM: 32.89±2.77 vs. 6.42±1.21, p value 0.0039, Fig. 6.2. II). Similar effects were observed as depleting intracellular calcium stores. BAPTA treatment resulted in significant inhibition of ICU COVID-19 IgG-induced Δψ depolarization (FI in % Δψ depolarization±SEM: 4.46±0.73 vs. 0.99±0.09, p value 0.0039, Fig. 7.1. A) and caspase 3 cleavage (Ratio of cleaved caspase 3/procaspase 3±SEM: 3.50±0.98 vs. 0.43±0.06, p value 0.0286, respectively, Fig. 7.1. B+C). In addition, BAPTA pretreatment of wPLTs resulted in marked prevention of ICU COVID-19 IgG-induced changes in FSC and SSC (Figure 7.2. A-D as well as significant reduction of CD62p/PS positive PLTs (% CD62p/PS positive PLTs: 29.58±3.36 vs. 1.74±0.39, p value 0.0020, Fig. 7.2. II). Activation of cAMP protects against ICU COVID-19 IgG induced procoagulant **PLTs** The interplay between the signalling pathways of the intracellular second messengers, cAMP and calcium, has been shown to have an important role in

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

numerous essential physiological processes during PLT activation and apoptosis (16. 17). Therefore, we investigated the role of cAMP on COVID-19 antibody-induced formation of procoagulant PLTs. Forskolin, an activator of intracellular ADC that elevates intracellular levels of cAMP, was recently reported to inhibit the formation of apoptotic PLTs in immune thrombocytopenia (18). The pretreatment of PLTs with Forskolin led to significant reduction of ICU COVID-19 IgG-induced Δψ depolarization (FI in % Δψ depolarization±SEM:5.10±0.70 vs. 1.43±0.17, p value 0.0079, Fig. 8.1. A) and caspase 3 cleavage (Ratio of cleaved caspase 3/procaspase 3±SEM: 3.74±1.14 vs. 1.01±0.14, p value 0.0313, respectively, Fig. 8.1. B+C). In addition, Forskolin pretreatment of wPLTs led to reduction of ICU COVID-19 IgG-induced changes in FSC and SSC properties (Fig. 8.2. A-D) as well as to a significant inhibition of procoagulant PLT generation (% CD62p/PS positive PLTs±SEM: 35.29±1.58 vs. 12.26±2.74, p value 0.0313, Fig. 8.2. II). These findings indicate that the elevation of intracellular cAMP prevents ICU COVID-19 IgG-induced formation of procoagulant PLTs. More importantly and of high clinical interest, similar protective effect was observed with Iloprost, an already approved cAMP inducer (19). In fact, Iloprost pretreatment of wPLTs led to marked reductions of ICU COVID-19 IgG-induced Δψ depolarization (FI of % Δψ depolarization±SEM: 4.66±0.57 vs. 1.77 ±0.32, p value 0.0078, Fig. 9.1. A), and cleavage of caspase 3 (Ratio of cleaved caspase 3/procaspase 3±SEM: 4.69±1.45 vs. 2.0348±0.38, p value 0.0156, respectively, Fig. 9.1. B+C). In addition, lloprost pretreatment led to a significant reduction of changes in PLT morphology (Fig. 9.2. A-D) as well as in the number of procoagulant CD62p/PS positive PLTs (% CD62p/PS positive PLTs±SEM: 41.36±3.60 vs. 22.22±3.92, p value 0.0156, Fig. 9.2. II). Noteworthy, no significant changes were

400

401

402

403

404

405

406

407

observed in the number of CD62p single positive PLTs (% CD62p positive PLTs±SEM: 24.48±2.2 vs. 26.51±3.94, p value 0.6875). Based on these findings we were interested whether Iloprost might affect the ability to form blood clots. Pretreatment of PLTs with Iloprost showed a marked reduction in ICU COVID-19 IgG-induced clot formation compared to vehicle (mean % SAC±SEM: 14.63±2.31 vs. 3.85±0.95, respectively, p value 0.0079, Fig. 10. A+B). These findings provide the first evidence for a potential therapeutic use of lloprost in the treatment of the antibody-induced coagulopathy that is observed in COVID-19 disease.

## **Discussion**

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

Our study showed that IgGs from patients with severe COVID-19 are able to induce procoagulant PLTs with increased potential for clot formation via crosslinking FcγRIIA in a calcium depending manner. Most importantly, we showed that cAMP activation by an approved drug, namely lloprost, can sufficiently inhibit the initiation of procoagulant PLTs and the subsequent increased clot formation. These data may have tremendous clinical implications.

Meanwhile, it is well established that COVID-19 infection is associated with systemic prothrombotic state and increased incidence of thromboembolic complications (20). However, the pre-sequelae events leading to the coagulopathy observed in COVID-19 still remains elusive. Data from our study demonstrate the presence of PLT-reactive IgG antibodies that harbour the ability to induce marked changes in PLTs in terms of increased Δψ depolarization, PS externalization and Pselectin expression, which are characteristic for procoagulant PLTs. A novel finding, and potentially of high clinical interest, is that antibody-mediated formation of procoagulant PLTs was associated with the clinical course as these changes progressively increased as patients needed ventilation and peaked between day 3 and 7 on ICU. Probably, the kinetic of these markers might have predictive value to monitor COVID-19-induced coagulopathy. In fact, PS externalization was recently found to be a predictive biomarker for thromboembolic complications related to cardiovascular therapeutic devices (21). In contrast to PS, conventional markers of PLT activation were declared in this study to fail the detection of early activation events leading to thrombosis.

The alterations in PLTs that were observed in our study after incubation with sera from patients with severe COVID-19 infection, such as  $\Delta\psi$  disruption, caspase 3

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

cleavage and PS externalization, could be found in apoptotic as well as procoagulant PLTs. The involvement of PLT apoptosis to promote prothrombotic conditions has been controversially discussed. In fact, recent data suggests that apoptotic PLTs are unable to promote prothrombotic conditions (10). However, a clear dissection of the molecular events leading to prothrombotic PLTs is challenging since activation of the apoptosis caspase pathway has been described in the late phase of agonist-induced PLT activation as well as in PLTs from patients with chronic kidney disease (22, 23), which are prone to thromboembolic events. Our findings showed that antibodymediated Δψ disruption and caspase cleavage is associated with the induction of a CD62p/PS positive PLT population suggesting that IgG antibodies in COVID-19 induce procoagulant rather than apoptotic PLTs. In fact, activated PLTs were shown elsewhere to be predominant in COVID-19 patients (6). In particular, CD62p positive PLTs were suggested to be involved in thrombosis in COVID-19 via the interaction with neutrophil granulocytes leading to NET formation and increased interaction with the inflamed vessel wall. Our data showed that COVID-19 IgG-antibodies trigger a PLT population with procoagulant potential. An important finding that was reinforced by data from an ex vivo microfluidic circulation system which revealed an increased clot formation in the presence of COVID-19 IgG-antibodies. Motivated by these novel functional data, we thought to dissect the exact

mechanistic pathways involved in the COVID-19 IgG-induced procoagulant status. We found that ICU COVID-19 IgG-mediated changes in wPLTs involves the ligation of the immune receptor FcγRIIA. The blockade of FcγRIIA significantly inhibits ICU COVID-19 IgG-induced changes in Δψ depolarization as well as cleavage of caspase 3. Most importantly, FcγRIIA blockade reduced procoagulant CD62p/PS positive PLTs and subsequently inhibited COVID-19 antibody-induced ex vivo clot formation. While this findings are novel for COVID-19-associated coagulopathy, the correlation

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

between FcγRIIA ligation and increased risk for thromboembolic events is well established for heparin-induced thrombocytopenia (HIT) (24). Interestingly, the IgG antibody formation peaks in HIT within 5-10 day after exposure to heparin and is associated with PLT consumption and increased risk for thrombosis (25). Similarly, in our study the ability of ICU COVID-19 sera to induce procoagulant PLTs was most pronounced between day 3 and 7. Of note, antibody-induced alterations in PLT markers were accompanied by enhanced levels of IgG antibodies against the Spike S epitope of SARS-CoV-2. These findings might suggest a transient onset of misdirected autoimmune mechanisms that result in the emergence of PLT-reactive antibodies leading to a prothrombotic status in severe COVID-19 infection.

Calcium is involved in many biological mechanistic pathways in PLTs (16). In response to PLT agonists, calcium is released from the PLT internal stores which is followed by amplifying second wave extracellular calcium influx via store (SOCE) and receptor operated calcium entry (ROCE), respectively (26). The role of calcium signalling in ITAM (immunoreceptor tyrosine-based activation motif) coupled GPVI and (hem)ITAM coupled CLEC-2 receptor signalling has been well established in the last few years (27). Additionally, FcyRIIA ligation has been shown to induce calcium mobilization via ITAM signalling prior to platelet aggregation (28). In our study, the depletion of calcium in the extracellular compartment inhibited ICU COVID-19 IgGinduced procoagulant changes. This finding indicates that alterations in SOCE or ROCE might be involved in the antibody-mediated generation of procoagulant PLTs in COVID-19. In fact, the regulative role of SOCE for procoagulant PS externalization has been previously reported, as SOCE channel inhibition resulted in reduced PS externalization in human erythroleukemia cells (29). In addition, reduced PS externalization and decreased clot formation was observed in chimeric mice that express mutated impaired SOCE calcium channel Orai1 R93W on the PLT surface,

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

indicating that SOCE is a major inductor of PLT PS externalization and procoagulant PLT formation (30). A potential role of ITAM-regulated signalling leading to procoagulant PLTs has been also suggested. Calcium depletion inhibited GP VI induced formation of procoagulant PLTs (31). In this study, the authors proposed that distinct signalling cascades, most likely tyrosine and extracellular calcium dependent, could be involved in the formation of procoagulant PLTs. Our findings emphasize the role of extracellular calcium in FcyRIIA (ITAM) mediated procoagulant PLT formation. Another possible explanation for these finding could be the loss of distinct calciumdependent conformational properties of PLT epitopes that are targeted by COVID-19 IgG antibodies. Dimeric PLT GP IIb/IIIa, the receptor for fibrinogen and well known immunogenic epitopes of PLT-reactive autoantibodies in immune thrombocytopenia (ITP), has been well characterized to be structurally dependent on extracellular calcium levels (32). Although this might be currently too speculative, the depletion of extracellular calcium might have inhibited antibody binding to such conformationsensitive epitopes on GP IIb/IIIa. ICU COVID-19 IgG-induced PLT alterations were dependent on extracellular as well as intracellular calcium levels. Since PLT apoptosis has been described to be independent of calcium (33), our finding indicates that COVID-19 IgGs trigger FcyRIIA -mediated events that result in procoagulant PLT formation in a calcium-dependent manner. In fact, similar findings were reported by recently showing that actin-mediated PLT shape change and phosphoinositide 3-kinase activity in response to FcvRIIA ligation in dependent on intracellular calcium (28). The absence of ICU COVID-19 IgG-mediated PLT changes could be also due to inactivation of calcium dependent cysteine protease calpain that is crucial for the conformational changes in GP IIb/IIIa (34, 35). Another possible explanation could be the inactivation of calcium dependent TMEM16F that bears essential properties for membrane phospholipid scrambling and microparticle

generation (10). Future studies could explore the exact mechanisms by which calcium contributes to procoagulant PLT formation in COVID-19.

COVID-19 antibody-induced procoagulant PLTs were significantly inhibited by the use of inducers of adenylate cyclase (ADC) that are well known to cause increased cAMP levels in PLTs (36). The protective effect of cAMP was further demonstrated, as lloprost, an already approved prostacyclin derivate and ADC, efficiently prevented the formation of procoagulant PLTs in response to COVID-19 antibodies. Finally and of high clinical importance, lloprost pretreatment of PLTs markedly reduced COVID-19 IgG-induced clot formation on collagen suggesting that cAMP inducers may have potential to prevent life threatening thromboembolic events in COVID-19 antibody-mediated coagulopathy. Another minor finding from our microfluidic system was that lloprost, although significantly inhibited antibody-mediated thrombus formation, did not affect the CD62p-single positive population. Since lloprost prevented clot formation, this finding might indicate that PS rather than CD62p exposure on the PLT surface is pivotal to trigger the onset of thromboembolic events.

Our study is subjected to some limitations. First, as an observational, monocentric study, we cannot conclude that the reported associations between IgG antibodies and changes in activation/apoptosis markers in COVID-19 are causal for the thrombosis or specific for the disease. Second, we cannot exclude the possibility of remaining residual confounding or unmeasured potential confounders in our mechanistic studies. Third, the low number of patients does not enable a final and robust statistical analysis to assess clinical outcomes in patients with increased procoagulant PLTs. Nevertheless, data presented in this study may provide a background for future studies to dissect mechanisms related to PLT activation that are involved in the progression of COVID-19.

Taken together, our study shows that IgG antibodies from patients with severe COVID-19 are able to stimulate FcγRIIA leading to the induction of procoagulant PLTs with an increased ability of clot formation. These processes are dependent on calcium and can be efficiently inhibited by cAMP inducers suggesting that ADC might represent a potentially promising target to prevent thromboembolic complications in COVID-19 disease.

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

**Author contributions** J.Z., K.A., T.B. and P.R. designed the study. P.R. and H.H. were responsible for the treatment of the patients. K.A. and H.H. collected and analyzed the clinical data. J.Z., K.A., H.J., L.P., A.S. and A.W. performed the experiments. J.Z., K.A., H.J., L.P., A.S. and A.W. collected the data. J.Z., K.A., H.J., L.P., A.S., A.W., V.M., P.R. and T.B. analyzed the data, interpreted the results and wrote the manuscript. All authors read and approved the manuscript. **Conflict of interest** The authors have no conflict of Interests. **Acknowledgements** This work was supported by grants from the "Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg" to J.Z. and T.B. and from the Herzstiftung to T.B. (BA5158/4 and TSG-Study) and TÜFF-Gleichstellungsförderung to K.A. (2563-0-0). We thank Karoline Weich for her excellent technical support. The authors thank Susanne Staub for editing the article as native English speaker.

Figure legends

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

Fig. 1-ICU COVID-19 patient serum induced effects on PLTs during disease. (A+B) ICU COVID-19 (n=26) or ICU non-COVID-19 control (n=5) patient serum induced changes in  $\Delta \psi$  as well as PS externalization in wPLTs were analyzed by FC. (C+D) Sera of 4 ICU COVID-19 patients were collected for up to 14 days during hospitalization and analyzed for their ability to induce changes in Δψ as well as PS externalization in wPLTs via FC. (E) Representative WB image of detected cleaved caspase 3 (cleaved-) and procaspase 3 (pro-) levels in wPLTs that were incubated with follow up sera of one ICU COVID-19 patient (indicated in C+D). (F) Densitometric analysis of cleaved caspase 3/procaspase 3 ratios in wPLTs that were incubated with follow up sera of ICU COVID-19 patients (n=4, [indicated in C+D]) normalized to control. α-Tubulin served as loading control. Data are presented as mean±SEM of the measured fold increase compared to control. ns, not significant; \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 and \*\*\*\*p<0.0001. The number of patient sera tested is reported in each graph. Dot lines in (A+B) represent the calculated cutoffs determined testing sera from healthy donors as mean of fold increase (FI)+2xSEM. HC, healthy control; Δψ, inner mitochondrial transmembrane potential; N, number of HCs or patients; PS, phosphatidylserine. Fig. 2-ICU COVID-19 IgGs induce procoagulant PLTs and increased clot formation. Fig. 2.1. (A+C) Representative FC plots of wPLTs' FSC vs. SSC properties after HC or ICU COVID-19 IgG incubation. (B+D) Following HC or ICU COVID-19 IgG incubation, CD42a positive gated wPLTs were analyzed for PS externalization and

expression of CD62p via Annexin V-FITC and CD62p-APC antibody staining,

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

respectively. Fig. 2.1. (I-IV) represent quantitative gate distribution of CD42a positive events as indicated in Fig. 2.1. (B+D). Data are shown as percentage±SEM of Annexin V-FITC and or CD62p-APC positive labeled wPLTs after incubation with HC (n=8), ICU non-COVID-19 (n=5) or ICU COVID-19 IgG (n=10). ns, not significant; \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 and \*\*\*\*p<0.0001. The number of patients and healthy donors tested is reported in each graph. HC, healthy control: N, number of HCs or patients; PS, phosphatidylserine. Fig. 3-ICU COVID-19 IgG cause increased clot formation on collagen. (A) PRP from healthy individuals with the blood group O was incubated with HC (n=6), ICU non-COVID-19 control (n=3) or ICU COVID-19 IgG (n=10), labelled with FITC conjugated calcein and perfused through microfluidic channels at a shear rate of 1500<sup>-1</sup> (60 dyne) for 5 min after reconstitution into autologous whole blood. Images were aguired at x20 magnification in the fluorescent (upper panel) as well as in the BF channel (lower panel). Scale bar 50µm. (B) Mean percentage of surface area covered (mean % SAC)±SEM by thrombus in the presence of HC (n=6), ICU non-COVID-19control (n=3) and ICU COVID-19 (n=10) IgG after 5 min perfusion time. ns, not significant; \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 and \*\*\*\*p<0.0001. The number of patients and healthy donors tested is reported in each graph. HC, healthy control; N, number of HCs or patients. Fig. 4-ICU COVID-19 IgG induced formation of procoagulant PLTs is FcyRIIA dependent. Fig. 4.1. (A) ICU COVID-19 patient serum (n=10) induced changes of  $\Delta \psi$  in wPLTs were analyzed in the presence or absence of moAb IV.3 via FC. Data are presented as mean±SEM of the measured fold increase compared to control. (B+C)

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

Representative WB image of detected cleaved caspase 3 (cleaved-) and procaspase 3 (pro-) levels in wPLTs that were incubated with ICU COVID-19 IgG (n=4) in the presence or absence of moAb IV.3. α-Tubulin served as loading control. (C) Densitometric analysis of cleaved caspase 3/procaspase 3 ratios from immunoblots as indicated in (B, n=4) normalized to control. Fig. 4.2. (A+C) Representative FC plots of wPLTs' FSC vs. SSC after ICU COVID-19 IgG incubation in IV.3 pretreated wPLTs. (B+D) Gate distribution of CD42a positive PS (Annexin V-FITC) externalizing and CD62p (CD62p-APC) expressing wPLTs after ICU COVID-19 IgG incubation in isotype control or IV.3 pretreated wPLTs. Fig. 4.2. (I-IV) shows quantitative gate distributions of wPLTs with or without IV.3 pretreatment, after ICU COVID-19 IgG incubation as shown in Fig. 4.2. (B+D). Data are presented as percentage±SEM of Annexin V-FITC and or CD62p-APC positive labeled wPLTs after incubation with HC (n=3) or ICU COVID-19 IgG (n=8) in the presence or absence of moAb IV.3. ns, not significant; \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 and \*\*\*\*p<0.0001. The number of patients and healthy donors tested is reported in each graph. HC, healthy control; N, number of HCs or patients; PS, phosphatidylserine. Fig. 5-FcyRIIA inhibition prevents ICU COVID-19 IgG induced increased clot formation. (A) PRP from healthy individuals with the blood group O was incubated with HC (n=2) or ICU COVID-19 IgG (n=3 patients) in the presence of moAb IV.3 or isotype control (moAb) and perfused through microfluidic channels at a shear rate of 1500<sup>-1</sup> (60 dyne) for 5 min. Images were aguired at x20 magnification in fluorescent (upper panel) as well as in the BF channel (lower panel). Scale bar 50µm. (B) mean % SAC±SEM induced by HC (n=2) or ICU COVID-19 IgG (n=3) in the presence or absence of moAb IV.3 or isotype control (moAb). ns, not significant; \*p<0.05,

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

\*\*p<0.01, \*\*\*p<0.001 and \*\*\*\*p<0.0001. The number of patients and healthy donors tested is reported in each graph. moAb, monoclonal isotype control; HC, healthy control; N, number of HCs or patients Fig. 6-ICU COVID-19 IgG induced formation of procoagulant PLTs is dependent on extracellular calcium. Fig. 6.1. (A) FC assessment of ICU COVID-19 IgG (n=5) induced changes of Δψ in wPLTs that were pretreated with EGTA (1 mM) or vehicle. Data are presented as mean±SEM of the measured fold increase compared to control. (B+C) Representative WB image of detected cleaved caspase 3 (cleaved-) and procaspase 3 (pro-) levels in EGTA (1 mM) vehicle pretreated wPLTs that were incubated with ICU COVID-19 IgG (n=6), respectively.  $\alpha$ -Tubulin served as loading control. (**C**) Densitometric analysis of immunoblots indicated in (B) for cleaved caspase 3/procaspase 3 ratios from WB data as indicated in (B, [n=5]) normalized to control. Fig. 6.2. (A+C) Representative FC plots of wPLTs' FSC vs. SSC after ICU COVID-19 lqG incubation in EGTA (1mM) or vehicle pretreated wPLTs. (B+D) Gate distribution of CD42a positive PS (Annexin V-FITC) externalizing and CD62p (CD62p-APC) expressing wPLTs after ICU COVID-19 IgG incubation in EGTA (1mM) or vehicle pretreated wPLTs. Fig. 6.2. (B+D) Gate distribution of CD42a positive PS (Lactadherin-FITC) externalizing and CD62p (CD62p-APC) expressing wPLTs after ICU COVID-19 IgG incubation in EGTA (1 mM) or vehicle containing wPLTs. Fig. **6.2.** (I-IV) shows quantitative gate distribution of wPLTs after incubation with ICU COVID-19 IgG. Data are presented as percentage±SEM of Lactadherin-FITC or CD62p-APC positive labeled wPLTs after incubation with HC (n=3) or ICU COVID-19 IgG (n=9) in vehicle or EGTA (1 mM) pretreated wPLTs. ns, not significant; \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 and \*\*\*\*p<0.0001. The number of patients and healthy donors

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

perpetuity.
All rights reserved. No reuse allowed without permission.

tested is reported in each graph. HC, healthy control; N, number of HCs or patients; PS, phosphatidylserine. Fig. 7-Depletion of intracellular calcium abrogates ICU COVID-19 IgG induced procoagulant PLT formation. Fig. 7.1 (A) ICU COVID-19 IgG (n=9) induced changes of  $\Delta \psi$  in wPLTs were analyzed in the presence or absence of the intracellular calcium chelator BAPTA (20 μM). (**B)** Representative WB image of cleaved caspase 3 (cleaved-) and procaspase 3 (pro-) were detected with anti-caspase 3 antibody in wPLTs that were incubated with ICU COVID-19 IgG in BAPTA (20 μM) or vehicle pretreated wPLTs. α. Tubulin served as loading control. (C) Densitometric analysis of cleaved caspase 3/procaspase 3 ratios from immunoblots (indicated in **B**, [n=4]) normalized to control. Fig. 7.2. (A+C) FC plots of wPLTs' FSC and. SSC after ICU COVID-19 IgG incubation in vehicle or BAPTA (20 µM) preloaded wPLTs. (B+D) FC plots of CD42a positive gated wPLTs that were incubated with ICU COVID-19 IgG in vehicle or in BAPTA (20 µM) preloaded wPLTs. Fig. 7.2.(I-IV) quantitative gate distribution of CD42a positive wPLTs based on the gate settings shown in Fig. 7.2. (B+D). Data are shown as percentage±SEM of Lactadherin-FITC and or CD62p-APC positive labeled wPLTs after HC (n=3) or ICU COVID-19 IgG (n=10) incubation in normal or BAPTA (20 μM) preloaded wPLTs. Ns,not significant; \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 and \*\*\*\*p<0.0001. The number of patients and healthy donors tested is reported in each graph. HC, healthy control; N, number of HCs or patients, PS; phosphatidylserine. Fig. 8-Forskolin protects ICU COVID-19 IgG induced procoagulant PLT formation.

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

Fig. 8.1. (A) FC analysis of ICU COVID-19 IgG (n=5 patients) induced changes in Δψ of wPLTs, that were pretreated with vehicle or the ADC inductor Forskolin (2.25 µM) for 30 min at 37°C. Data are presented as mean±SEM of the measured fold increase compared to control. (B) Representative WB image of cleaved caspase 3 (cleaved-) and procaspase 3 (pro-) levels detected in wPLTs that were incubated with ICU COVID-19 IgG in vehicle or Forskolin (2.25 μM) pretreated wPLTs. α-Tubulin served as loading control. (C) Densitometric assessed ratios of cleaved caspase 3/procaspase 3 (as indicated in B [n=6]) normalized to control. Fig. 8.2. (A+C) FC plots of wPLTs' FSC vs. SSC after ICU COVID-19 IgG incubation in vehicle or Forskolin (2.25 µM) pretreted wPLTs. (**B+D**) Gate distribution of CD42a positive wPLTs that were incubated with ICU COVID-19 IgG vehicle or Forskolin (2.25 μM) pretreated wPLTs. Fig. 8.2. (I-IV) Quantitative distribution of CD42a positive wPLTs based on the gate settings shown in Fig. 8.2. (B+D). Data are shown as percentage ±SEM of Annexin V-FITC and or CD62p-APC positive labeled wPLTs that were incubated with IgGs from HC (n=3) or ICU COVID-19 IgG (n=6) in vehicle or Forskolin (2.25 µM) pretreated wPLTs. ns, not significant; \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 and \*\*\*\*p<0.0001. The number of patients and healthy donors tested is reported in each graph. HC, healthy control; N, number of HCs or patients; PS, phosphatidylserine.

- 712 Fig. 9-cAMP elevation via lloprost prevents ICU COVID-19 lgG induced 713 procoagulant PLTs.
- 714 Fig. 9.1. (A) Changes in Δψ depolarization induced by ICU COVID-19 IgG (n=8) 715 patients) were analyzed in vehicle or lloprost (20 nM) pretreated wPLTs via FC. Data

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

are presented as mean±SEM of the measured fold increase compared to control. (B) Representative WB image of detected caspase 3 (cleaved-) and procaspase 3 (pro-) levels in wPLTs that were pretreated with vehicle or Iloprost (20 nM) prior to ICU COVID-19 IgG incubation. α-Tubulin served as loading control. (C) Densitometric analysis of cleaved caspase 3/procaspase 3 ratios from the WB data (indicated in **B**, [n=7]) normalized to control. Fig. 9.2. (A+C) FC detected changes in wPLTs' FSC vs. SSC properties after ICU COVID-19 IgG incubation in vehicle or Iloprost (20 nM) pretreated wPLTs. Fig. 9.2. (B+D) (E+G) Gate distribution of CD42a positive vehicle or Iloprost (20 nM) pretreated wPLTs that were incubated with ICU COVID-19 lgG. Fig. 9.2. (I-IV) Quantitative distribution of the CD42a positive wPLT population based on the gate settings shown in Fig. 9.2. (B+D). Data are shown as percentage±SEM of Annexin V-FITC and or CD62p-APC positive labeled wPLTs that were incubated with HC (n=3) or ICU COVID-19 IgG (n=6) in vehicle or Iloprost (20 nM) pretreated wPLTs. ns, not significant; \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 and \*\*\*\*p<0.0001. The number of patients and healthy donors tested is reported in each graph. HC, healthy control; N, number of HCs or patients; PS, phosphatidylserine. Fig. 10-lloprost inhibits ICU COVID-19 IgG induced increased clot formation. (A) PRP from healthy individuals with the blood group O was incubated with HC (n=3) or ICU COVID-19 IgG (n=5) in the presence of vehicle or Iloprost (20 nM). After resonstituion into autologous whole blood, samples were perfused through microfluidic channels at a shear rate of 1500<sup>-1</sup> (60 dyne) for 5 min. Pictures were aguired at x20 magnification in fluorescent (upper panel) as well as in the BF channel (lower panel). Scale bar 50µm. (B) Mean % SAC±SEM induced by HC (n=3) or ICU COVID-19 IgG (n=5) in the presence of vehicle or lloprost (20 nM). ns,not significant; \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 and \*\*\*\*p<0.0001. The number of patients and healthy

All rights reserved. No reuse allowed without permission.

- donors tested is reported in each graph. HC, healthy control; N, number of HCs or
- 742 patients; PS, phosphatidylserine.

### References:

743

744

745746

- Thou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of
- $748 \qquad \text{adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet.} \\$
- 749 2020;395(10229):1054-62.
- Hanff TC, Mohareb AM, Giri J, Cohen JB, Chirinos JA. Thrombosis in COVID-19. Am J Hematol.
- 751 2020;95(12):1578-89.
- 3. Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of Coronavirus Disease 2019. Crit Care Med. 2020;48(9):1358-64.
- Henry BM, Vikse J, Benoit S, Favaloro EJ, Lippi G. Hyperinflammation and derangement of
- renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected
- hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta. 2020;507:167-73.
- 757 5. Hottz ED, Azevedo-Quintanilha IG, Palhinha L, Teixeira L, Barreto EA, Pao CRR, et al. Platelet
- activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood. 2020;136(11):1330-41.
- 760 6. Manne BK, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben C, et al. Platelet gene expression and function in patients with COVID-19. Blood. 2020;136(11):1317-29.
- 762 7. de Witt SM, Verdoold R, Cosemans JM, Heemskerk JW. Insights into platelet-based control of coagulation. Thromb Res. 2014;133 Suppl 2:S139-48.
- Swieringa F, Spronk HMH, Heemskerk JWM, van der Meijden PEJ. Integrating platelet and coagulation activation in fibrin clot formation. Res Pract Thromb Haemost. 2018;2(3):450-60.
- 766 9. Agbani EO, Poole AW. Procoagulant platelets: generation, function, and therapeutic targeting in thrombosis. Blood. 2017;130(20):2171-9.
- 768 10. Reddy EC, Rand ML. Procoagulant Phosphatidylserine-Exposing Platelets in vitro and in vivo.
- 769 Front Cardiovasc Med. 2020;7:15.
- 770 11. Hua VM, Chen VM. Procoagulant platelets and the pathways leading to cell death. Semin
- 771 Thromb Hemost. 2015;41(4):405-12.
- The second of th
- heparin-associated thrombocytopenia. Thromb Haemost. 1991;66(6):734-6.
- 774 13. Marini I, Zlamal J, Faul C, Holzer U, Hammer S, Pelzl L, et al. Autoantibody-mediated
- desialylation impairs human thrombopoiesis and platelet life span. Haematologica. 2019.
- 776 14. Mangin PH, Gardiner EE, Nesbitt WS, Kerrigan SW, Korin N, Lam WA, et al. In vitro flow based
- systems to study platelet function and thrombus formation: Recommendations for standardization:
- 778 Communication from the SSC on Biorheology of the ISTH. J Thromb Haemost. 2020;18(3):748-52.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with
- 780 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
- 781 16. Mammadova-Bach E, Nagy M, Heemskerk JWM, Nieswandt B, Braun A. Store-operated
- 782 calcium entry in thrombosis and thrombo-inflammation. Cell Calcium. 2019;77:39-48.
- 783 17. Nagy Z, Smolenski A. Cyclic nucleotide-dependent inhibitory signaling interweaves with
- activating pathways to determine platelet responses. Res Pract Thromb Haemost. 2018;2(3):558-71.
- 785 18. Zhao L, Liu J, He C, Yan R, Zhou K, Cui Q, et al. Protein kinase A determines platelet life span
- and survival by regulating apoptosis. J Clin Invest. 2017;127(12):4338-51.

All rights reserved. No reuse allowed without permission.

- 787 19. Fisch A, Michael-Hepp J, Meyer J, Darius H. Synergistic interaction of adenylate cyclase
- activators and nitric oxide donor SIN-1 on platelet cyclic AMP. Eur J Pharmacol. 1995;289(3):455-61.
- 789 20. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor
- 790 prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-7.
- 791 21. Roka-Moiia Y, Walk R, Palomares DE, Ammann KR, Dimasi A, Italiano JE, et al. Platelet 792 Activation via Shear Stress Exposure Induces a Differing Pattern of Biomarkers of Activation versus
- 793 Biochemical Agonists. Thromb Haemost. 2020;120(5):776-92.
- 794 22. Shcherbina A, Remold-O'Donnell E. Role of caspase in a subset of human platelet activation 795 responses. Blood. 1999;93(12):4222-31.
- 796 23. Bonomini M, Dottori S, Amoroso L, Arduini A, Sirolli V. Increased platelet phosphatidylserine
- 797 exposure and caspase activation in chronic uremia. J Thromb Haemost. 2004;2(8):1275-81.
- 798 24. Chong BH, Fawaz I, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia:
- mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol.
- 800 1989;73(2):235-40.
- 801 25. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia (HIT) and its
- differentiation from non-HIT thrombocytopenia. Thromb Haemost. 2016;116(5):813-22.
- Rink TJ, Sage SO. Calcium signaling in human platelets. Annu Rev Physiol. 1990;52:431-49.
- 804 27. Rayes J, Watson SP, Nieswandt B. Functional significance of the platelet immune receptors
- 805 GPVI and CLEC-2. J Clin Invest. 2019;129(1):12-23.
- 806 28. Barkalow KL, Falet H, Italiano JE, Jr., van Vugt A, Carpenter CL, Schreiber AD, et al. Role for
- phosphoinositide 3-kinase in Fc gamma RIIA-induced platelet shape change. Am J Physiol Cell Physiol.
- 808 2003;285(4):C797-805.
- 809 29. Kunzelmann-Marche C, Freyssinet JM, Martinez MC. Regulation of phosphatidylserine
- transbilayer redistribution by store-operated Ca2+ entry: role of actin cytoskeleton. J Biol Chem.
- 811 2001;276(7):5134-9.
- 812 30. Bergmeier W, Oh-Hora M, McCarl CA, Roden RC, Bray PF, Feske S. R93W mutation in Orai1
- causes impaired calcium influx in platelets. Blood. 2009;113(3):675-8.
- 814 31. Heemskerk JW, Vuist WM, Feijge MA, Reutelingsperger CP, Lindhout T. Collagen but not
- fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine, and procoagulant activity
- of adherent platelets: evidence for regulation by protein tyrosine kinase-dependent Ca2+ responses.
- 817 Blood. 1997;90(7):2615-25.
- 818 32. Tomiyama Y, Kosugi S. Autoantigenic epitopes on platelet glycoproteins. Int J Hematol.
- 819 2005;81(2):100-5.
- 820 33. Schoenwaelder SM, Yuan Y, Josefsson EC, White MJ, Yao Y, Mason KD, et al. Two distinct
- pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood.
- 822 2009;114(3):663-6.

830

- 823 34. Mattheij NJ, Gilio K, van Kruchten R, Jobe SM, Wieschhaus AJ, Chishti AH, et al. Dual
- mechanism of integrin alphallbbeta3 closure in procoagulant platelets. J Biol Chem.
- 825 2013;288(19):13325-36.
- 826 35. Kulkarni S, Jackson SP. Platelet factor XIII and calpain negatively regulate integrin
- alphallbbeta3 adhesive function and thrombus growth. J Biol Chem. 2004;279(29):30697-706.
- 828 36. Smolenski A. Novel roles of cAMP/cGMP-dependent signaling in platelets. J Thromb
- 829 Haemost. 2012;10(2):167-76.






Figure 2.1. Figure 2.1. В Α N= 10 10 1007 100-CD62p/PS pos. PLTs % Annexin V-FITC \*\*\*\* 10<sup>2</sup> -80-DS 101 60-40-10<sup>0</sup> -20 20-10<sup>1</sup> 10<sup>2</sup> 10° 10<sup>2</sup> SSC CD62p-APC ICU COVID-19 ICU COVID-19 ICU ICU Control Control HC С D IV Ш N= 10 1007 100-Annexin V-FITC 10<sup>2</sup> -CD62p/PS neg. PLTs % CD62p pos. PLTs % 80-80-60-60-10<sup>0</sup> **IV** Ш 40-10<sup>1</sup> 10<sup>2</sup> 20-SSC CD62p-APC **ICU COVID-19** ICU COVID-19 ICU COVID-19 ICU HC ICU Control Control

Figure 3 A




**ICU COVID-19** 

Control




В

Figure 4.1.











Figure 4.2. I-IV Figure 4.2. **ICU COVID-19** Ш В Α 100-CD62p/PS pos. PLTs % % SLTs % 60 40 40 20 80-Annexin V-FITC 10<sup>2</sup> -60-FSC 40-100 - IV Ш 20-10<sup>2</sup> IV.3 IV.3 10<sup>1</sup> SSC CD62p-APC нс ICU COVID-19 HC ICU COVID-19 +isotype control С D IV Ш N= 100 CD62p/PS neg. PLTs % Annexin V-FITC CD62p pos. PLTs % ns 80-<del>V</del> S 102 ns DS 101 60-60-Ш 10<sup>1</sup> 10<sup>2</sup> IV.3 IV.3 CD62p-APC SSC ICU COVID-19 ICU COVID-19 нс нс +IV.3

Figure 5



В






Figure 6.1.





 $\alpha$  -Tubulin


Cleaved-


Pro-

+

Figure 6.2. I-IV Figure 6.2. **ICU COVID-19** В Α Ш 100-CD62p/PS pos. PLTs % ns Lactadherin-FITC PS pos. PLTs % 10<sup>2</sup> -60-FSC 40-20 **EGTA EGTA** SSC CD62p-APC ICU COVID-19 ICU COVID-19 нС нС +Vehicle С D IV Ш CD62p/PS neg. PLTs % CD62p pos. PLTs % Lactadherin-FITC 80-80-10<sup>2</sup> -60-60-FSC 20-능 10<sup>1</sup> 10<sup>2</sup> 10<sup>2</sup> 10<sup>1</sup> **EGTA EGTA** SSC CD62p-APC ICU COVID-19 ICU COVID-19 HC HC +EGTA

Figure 7.1.











Figure 7.2. I-IV Figure 7.2. **ICU COVID-19** В Α Ш 10 10 10 10 100-CD62p/PS pos. PLTs % 80 80 PS pos. PLTs % Lactadherin-FITC 10<sup>2</sup> ns 60 60-FSC 101 20-**BAPTA BAPTA** 10<sup>2</sup> ICU COVID-19 ICU COVID-19 SSC CD62p-APC HC HC +Vehicle С D IV Ш 10 10 100-CD62p/PS neg. PLTs % CD62p pos. PLTs % Lactadherin-FITC 80-80. 10<sup>2</sup> -60 60 DS 101 10<sup>1</sup> 40 10<sup>0</sup> -10<sup>2</sup> **BAPTA BAPTA** CD62p-APC SSC ICU COVID-19 нс ICU COVID-19 нс +BAPTA

Figure 8.1.













Figure 9.1.












Figure 10

